Moderna will pay up to $2.25B to settle a patent lawsuit over lipid nanoparticle technology used in its COVID-19 vaccine.
Moderna Inc.’s settlement to end a lawsuit over technology used in its Covid-19 vaccine caps its potential exposure at $2.25 ...
Announced days before a trial, the deal settles a longstanding dispute and avoids what one analyst called a “worst-case scenario” financially for Moderna.
BioNTech SE BNTX has filed a patent infringement lawsuit against Moderna Inc. MRNA, alleging that Moderna's next-generation COVID-19 vaccine, mNEXSPIKE, relies on proprietary technology developed and ...
A settlement provides a massive windfall for Arbutus and Roivant and avoids a worst-case scenario for Moderna.
Moderna (MRNA) stock rises as a $950M payment to resolve a patent dispute with Arbutus (ABUS) and Roivant (ROIV) lifts a key legal overhang. Read more here.
Moderna, Inc. settles LNP patent dispute for $950M, securing royalty-free tech access and legal clarity. Find out why MRNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results